*Communicable Diseases Intelligence*, Year 2023, Volume

https://doi.org/10.33321/cdi.2023.47.52

Publication date: 21/09/2023

<http://health.gov.au/cdi>

Group B streptococcus in the Northern Territory in 2023: clindamycin down but not out

Kate Proudmore, Ma Nu Nu Swe, May Leitch, Kim Clayfield, Jann Hennessy, Rob Baird

Streptococcus agalactiae, or group B streptococcus (GBS), is a significant cause of perinatal morbidity and mortality;1,2 however, prophylactic antibiotics can mitigate the risk of infection. The most important risk factor for neonatal GBS infection is maternal colonisation.1 In the Northern Territory (NT) of Australia, the incidence of neonatal early onset GBS is 0.36 per 1000 live births.2 The primary prophylactic agent for maternal administration to prevent neonatal GBS disease is penicillin, but for women who have a severe hypersensitivity to penicillin, recommendations include clindamycin as an alternative agent.3

In the adult population, GBS can cause a wide range of infections and effects most body systems.1 More invasive disease like meningitis can occur in the immunosuppressed population. GBS is a notable but infrequent cause of infective endocarditis and is also associated with wound and urinary tract infections.1

Group B streptococci are highly susceptible to penicillin, but there is emerging evidence of increasing resistance to erythromycin and clindamycin worldwide.4 The resistance patterns for macrolides stems from ribosomal modifications by methylation from encoded erm genes.5 Gene expression causing clindamycin resistance may be constitutive (c-MLSB phenotype) or induced by the presence of erythromycin (i-MLSB phenotype).6 More rarely, isolates may express lnu genes, resulting in susceptibility to erythromycin but resistance to clindamycin (L phenotype).5,6

Clindamycin resistance rates among GBS vary widely depending on geographic region and local prescribing practices. An Australia-wide survey using data to 2006 showed low clindamycin resistance rates of 4.2%.4 However, a 2022 study from New South Wales showed a higher clindamycin resistance rate of 32%.7 In the United States of America, the overall prevalence of clindamycin-resistant isolates was reported to be approximately 40% in 2019.8 In Europe, clindamycin resistance rates among GBS vary by country, with reported rates ranging from less than 10% to over 36%.9 In Asia, clindamycin resistance rates among GBS also vary by country but overall are higher: for example, a study in South Korea reported a clindamycin resistance rate of 55.4% amongst GBS isolates, while a study in China reported a resistant rate of 73.3% to clindamycin.10,11

Current NT public laboratory practice does not include routine antimicrobial susceptibility testing for GBS detected on antenatal screening swabs. We have conducted a review of GBS resistance to clindamycin and erythromycin in the Top End (which encompasses the northernmost section of the NT, covering an area in excess of 500,000 km2 with a sparse population of 180,000 and a distinct tropical monsoonal season).12 This review was undertaken to determine whether the current resistance testing practice and intrapartum antibiotic selection should be amended. This was a prospective study, looking at 113 sequential isolates sent to the public reference laboratory in the NT over a three-month period from January to March 2023. The isolates comprised wound swabs from various sites (47%); antenatal screening swabs (45%); urine cultures (4%); and sterile sites including blood cultures and intraoperative tissue (4%).

GBS was isolated using a variety of selective and chromogenic agars: Columbia horse blood agar (Thermo Fisher Scientific, TFS) and Columbia horse blood agar with colistin and nalidixic acid (TFS) for wound swabs; Brilliance UTI Agar (TFS) for urine and vaginal swabs; and Granada agar (TFS) for antenatal screening swabs. GBS was identified from Granada agar (TFS) by the presence of orange colonies.13 For all other agars, identification of GBS was confirmed using a Lancefield Streptococcal antigen grouping kit (Oxoid) or by matrix-assisted laser desorption-ionization time of flight (MALDI-TOF, Biomérieux) mass spectrometry. Antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI), employing the double disc diffusion method using a 15 µg erythromycin disc and a 2 µg clindamycin disc placed at an edge-to-edge distance of 12 mm.1,13 Inducible clindamycin resistance was detected by a ‘D test’: a positive ‘D test’, indicated by flattening/blunting of the clindamycin zone closest to the erythromycin disk, giving the appearance of a ‘D’, is consistent with a i-MLSB phenotype.1,13

The results reveal that 30% of GBS isolates tested were resistant to clindamycin. The GBS isolates were allocated categories according to resistance phenotypes (Table 1).1,13 Of these 34 clindamycin-resistant isolates, 28/34 (82%) showed constitutive resistance of the c-MLSB phenotype (23/34; 68%) or the L phenotype (5/34; 15%). Inducible resistance, i-MLSB phenotype, was found in 6/34 (18%) of the clindamycin-resistant isolates.

Table 1: Group B Streptococcus antimicrobial susceptibility data, Top End NT, January–March 2023

| Antibiotic | Susceptibility of GBS isolates |
| --- | --- |
| Susceptible, n (%) | Resistant, n (%) |
| Penicillin | 113 (100) | 0 |
| Vancomycin | 113 (100) | 0 |
| Erythromycin | 68 (60) | 45 (40) |
| Clindamycin | 79 (70) | 34 (30) |

Clindamycin therefore should only be used as an alternative to penicillin in colonised antenatal patients as prophylaxis where it has been proven susceptible, otherwise intravenous vancomycin is the suggested alternative.3

The Garland study of 2011 is still widely quoted, with their data demonstrating clindamycin resistance in 4.2% of GBS isolates.4 Our results concur with recent data revealing increasing clindamycin resistance around Australia (Table 2); however, not all jurisdictions have published their rates.

Table 2: Group B streptococcus clindamycin resistance rates within Australiaa

| Jurisdiction | Collection year | Clindamycin resistance rate (%) | Reference |
| --- | --- | --- | --- |
| Australia | 2006 | 4 | 4 |
| Australia | 2019 | 33 | 14 |
| New South Wales | 2020 | 12 | 15 |
| New South Wales | 2022 | 32 | 7 |
| Western Australia | 2021 | 40 | 16 |
| Northern Territory | 2023 | 30 | (this work) |

a No local published data was found for the Australian Capital Territory, Queensland, South Australia, Tasmania, or Victoria.

Within the Northern Territory, we found a resistance rate of 30% to clindamycin in our GBS isolates. The therapeutic guidelines, for GBS-positive antenatal patients with a severe (immediate or delayed) hypersensitivity to penicillin, recommend vancomycin.3 This sentence reads awkwardly. Is it that the authors make this recommendation on the basis of this study? If so, this might more clearly be expressed as ‘On the basis of our study, we recommend that antimicrobial susceptibility testing should be performed on all positive antenatal GBS screening swabs in the NT, in particular for patients with a severe (immediate or delayed) hypersensitivity to penicillin.. In addition, we should move away from clindamycin and consider vancomycin as first line for this cohort of patients whilst awaiting clindamycin susceptibility results. This has strong public health implications for the at-risk obstetric population within the NT. As a result of this research, we would suggest that other jurisdictions which have areas of a similar demographic population should undertake similar studies.

# Author details

Dr Kate E Proudmore,1,2,3

Mrs Ma Nu Nu Swe,2,3

Ms May Leitch,2,3

Mrs Kim Clayfield,2,3

Ms Jann Hennessy,2,3

A/Prof. Rob W Baird,2,4

1. Advanced Trainee Infectious Diseases and Acute and General Care Medicine.
2. Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
3. Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
4. Clinical Microbiologist and Director of Pathology, Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.

## Corresponding author

Dr Kate E Proudmore

Address: Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia

Phone: 0409 115 600

Email: kate.proudmore@nt.gov.au

# References

1. Spellerberg P, Brandt C. Streptococcus. In Versalovich J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, eds. Manual of Clinical Microbiology (10th Edition). Washington DC: American Society for Microbiology Press, 2011; 331–49. doi: https://doi.org/10.1128/9781555816728.ch20.
2. Yanni M, Stark M, Francis L, Francis JR, McMillan M, Baird R et al. Neonatal group B streptococcal infection in Australia: a case-control study. Pediatr Infect Dis J. 2023;42(5):429–35. doi: https://doi.org/10.1097/INF.0000000000003881.
3. Therapeutic Guidelines. Prevention of neonatal Streptococcus agalactiae (group B streptococcus) disease. [Internet.] Melbourne: Therapeutic Guidelines Limited; April 2019. [Accessed on 5 May 2023.] Available from: www.tg.org.au.
4. Garland SM, Cottrill E, Markowski L, Pearce C, Clifford V, Ndisang D et al. Antimicrobial resistance in group B streptococcus: the Australian experience. J Med Microbiol. 2011;60(Pt 2):230–5. doi: https://doi.org/10.1099/jmm.0.022616-0.
5. Hayes K, Cotter L, Barry L, O’Halloran F. Emergence of the L phenotype in Group B Streptococci in the South of Ireland. Epidemiol Infect. 2017;145(16):3535–42. doi: https://doi.org/10.1017/S0950268817002461.
6. Gygax SE, Schuyler JA, Kimmel LE, Trama JP, Mordechai E, Adelson ME. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob Agents Chemother. 2006;50(5):1875–7. doi: https://doi.org/10.1128/AAC.50.5.1875-1877.2006.
7. Jones S, Newton P, Payne M, Furfaro L. Epidemiology, antimicrobial resistance, and virulence determinants of group B streptococcus in an Australian setting. Front Microbiol. 2022;13:839079. doi: https://doi.org/10.3389/fmicb.2022.839079.
8. Kadri SS. Key takeaways from the U.S. CDC’s 2019 Antibiotic Resistance Threats Report for frontline providers. Crit Care Med. 2020;48(7):939–45. doi: https://doi.org/10.1097/CCM.0000000000004371.
9. Barcaite E, Bartusevicius A, Tameliene R, Kliucinskas M, Maleckiene L, Nadisauskiene R. Prevalence of maternal group B streptococcal colonisation in European countries. Acta Obstet Gynecol Scand. 2008;87(3):260–71. doi: https://doi.org/10.1080/00016340801908759.
10. Janapatla RP, Ho YR, Yan JJ, Wu HM, Wu JJ. The prevalence of erythromycin resistance in group B streptococcal isolates at a University Hospital in Taiwan. Microb Drug Resist. 2008;14(4):293–7. doi: https://doi.org/10.1089/mdr.2008.0853.
11. Ding Y, Wang Y, Hsia Y, Russell N, Heath PT. Systematic review and meta-analyses of incidence for group B streptococcus disease in infants and antimicrobial resistance, China. Emerg Infect Dis. 2020;26(11):2651–9. doi: https://doi.org/10.3201/eid2611.181414.
12. Australian Bureau of Statistics. Snapshot of Northern Territory. Highlevel summary data for Northern Territory in 2021. [Webpage.] Canberra: Australian Bureau of Standards; 28 June 2022. Available from: https://www.abs.gov.au/articles/snapshot-nt-2021.
13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Wayne, PA: CLSI; 2022.
14. The Antimicrobial Use and Resistance in Australia (AURA) Surveillance System. AURA 2021. Fourth Australian report on antimicrobial use and resistance in human health. Sydney: Australian Commission on Safety and Quality in Health Care; 2021. [Accessed on 17 May 2023.] Available from: https://www.safetyandquality.gov.au/sites/default/files/2021-08/AURA\_2021\_Fourth\_Australian\_report\_on\_antimicrobial\_use\_and\_resistance\_in\_human\_health.pdf.
15. The Royal Hospital for Women. Local operating procedure – clinical. Group B Streptococcus (GBS) Screening And Prophylaxis. Sydney: South Eastern Sydney Local Health District, the Royal Hospital for Women; June 2022. [Accessed on 17 May 2023.] Available from: https://www.seslhd.health.nsw.gov.au/sites/default/files/documents/GBSprophylaxis%202020.pdf.
16. Government of Western Australia North Metropolitan Health Service (NMHS). Obstetrics And Gynaecology Clinical Practice Guideline. Group B streptococcal disease. Perth: NMHS; 2021. [Accessed on 17 May 2023.] Available from: https://www.kemh.health.wa.gov.au/~/media/HSPs/NMHS/Hospitals/WNHS/Documents/Clinical-guidelines/Obs-Gyn-Guidelines/Group-B-Streptococcal-Disease.pdf.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Christina Bareja

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2023 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>